The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative Breast Cancer: A Systemic Review and Meta-Analysis.

[1]  Shengchun Liu,et al.  Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study , 2022, Frontiers in Oncology.

[2]  Ying Lin,et al.  Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer , 2022, Breast.

[3]  Sung-Bae Kim,et al.  Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy. , 2022, European journal of cancer.

[4]  G. Pruneri,et al.  Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world , 2022, Frontiers in Molecular Biosciences.

[5]  M. Küçüköner,et al.  Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy. , 2022, Future oncology.

[6]  F. Bertucci,et al.  Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers. , 2022, European journal of cancer.

[7]  Yang Yu,et al.  Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis , 2022, Annals of Surgical Oncology.

[8]  Yi-Feng Ren,et al.  Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions , 2022, Cancers.

[9]  M. Smid,et al.  HER2-low breast cancer shows a lower immune response compared to HER2-negative cases , 2022, Scientific Reports.

[10]  G. Curigliano,et al.  Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons. , 2022, Cancer discovery.

[11]  J. Rahnenführer,et al.  Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. , 2022, European journal of cancer.

[12]  Huina Zhang,et al.  HER2-low breast cancers: Current insights and future directions. , 2022, Seminars in diagnostic pathology.

[13]  S. Tyekucheva,et al.  Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. , 2022, JAMA oncology.

[14]  K. Shen,et al.  Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer , 2022, Breast Cancer.

[15]  Yang Luo,et al.  Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience , 2022, Frontiers in Oncology.

[16]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.

[17]  M. Fassan,et al.  HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment , 2022, npj Breast Cancer.

[18]  M. Campone,et al.  Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer , 2022, Cancers.

[19]  Y. Kim,et al.  Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society , 2022, Breast cancer research : BCR.

[20]  W. Han,et al.  HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis , 2022, BMC Medicine.

[21]  L. Pusztai,et al.  Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. , 2022, JAMA oncology.

[22]  Leonor Vasconcelos de Matos,et al.  Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer , 2022, Cureus.

[23]  R. Gelber,et al.  Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis , 2021, BMJ.

[24]  J. Ramos,et al.  Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers , 2021, Cancers.

[25]  P. Lollini,et al.  Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression , 2021, Oncogenesis.

[26]  M. Sarfaty,et al.  Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer , 2021, Breast.

[27]  P. Fasching,et al.  Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. , 2021, The Lancet. Oncology.

[28]  N. Pondé,et al.  HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer , 2021, Breast Cancer Research and Treatment.

[29]  H. Iwata,et al.  The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status , 2021, Breast Cancer.

[30]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[31]  F. Cardoso,et al.  HER2-Low Breast Cancer: Pathological and Clinical Landscape. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Pandy,et al.  Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review , 2019, BMC Cancer.

[33]  S. Y. Park,et al.  HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation , 2019, Journal of pathology and translational medicine.

[34]  M. Dowsett,et al.  HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. , 2018, Journal of oncology practice.

[35]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Schneeweiss,et al.  Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer , 2018, Investigational New Drugs.

[37]  Sung-Bae Kim,et al.  Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy , 2017, The New England journal of medicine.

[38]  Sridhar Ramaswamy,et al.  HER2 expression identifies dynamic functional states within circulating breast cancer cells , 2016, Nature.

[39]  T. Fehm,et al.  Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer , 2016, Journal of Cancer Research and Clinical Oncology.

[40]  Erin E Kepplinger,et al.  FDA's Expedited Approval Mechanisms for New Drug Products. , 2015, Biotechnology law report.

[41]  O. Yersal,et al.  Biological subtypes of breast cancer: Prognostic and therapeutic implications. , 2014, World journal of clinical oncology.

[42]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[43]  M. Dieci,et al.  Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. V. Van Bockstal,et al.  Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance. , 2013, American journal of clinical pathology.

[46]  R. Ponzone,et al.  Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. , 2012, The oncologist.

[47]  J. Cuzick,et al.  ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer , 2009, Breast Cancer Research.

[48]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.